Advertisement

Influence of buffy coat–derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts

  • Marius Otto
  • Sebastian Blatt
  • Andreas Pabst
  • Robert Mandic
  • Johanna Schwarz
  • Andreas Neff
  • Thomas ZiebartEmail author
Original Article
  • 17 Downloads

Abstract

Objectives

The aim of this murine in vivo study was to investigate whether buffy coat–derived putative endothelial progenitor cells (BCEPC) alter tumor growth and neovascularization in oral squamous cell carcinomas (OSCC).

Materials and methods

A murine xenograft model using the PCI-13 oral cancer cell line was deployed of which n = 24 animals received 2 × 106 BCEPC by transfusion whereas the control group (n = 24) received NaCl (0.9%) instead. Tumor size, volume, and capillary density were determined by sonography and measurement with a caliper. Immunohistochemical analysis was carried out with antibodies specific for Cytokeratins, Flt-4, Podoplanin, and Vimentin.

Results

In the experimental group, systemic application of BCEPC significantly increased tumor volume to 362.49% (p = 0.0012) and weight to 352.38% (p = 0.0018) as well as vascular densities to 162.15% (p = 0.0021) compared with control tumors. In addition, BCEPC-treated xenografts exhibited higher Cytokeratin expression levels by a factor of 1.47 (p = 0.0417), Podoplanin by a factor of 3.3 (p = 0.0020) and Vimentin by a factor of 2.5 (p = 0.0001), respectively.

Conclusions

Immunohistochemical investigations support the notion that BCEPC transfusion influences neovascularization and lymphatic vessel density, thereby possibly promoting tumor progression. Future studies, which will include gene expression analysis, should help to define the possible role of BCEPC during OSCC progression in more detail.

Clinical relevance

Endothelial progenitor cells (EPCs) could serve as a target structure for the treatment of OSCC and possibly other solid tumors.

Keywords

Oral cancer Endothelial progenitor cell Neovascularization Lymphangiogenesis 

Notes

Acknowledgements

The authors thank Dr. J. Goldschmitt (Laboratory of the Clinic for Oral and Maxillofacial Surgery, University Medical Center Mainz, Germany) as well as R. Peldszus and G. Sadowski (Interdisciplinary Head & Neck Oncology Laboratory, Department of Otolaryngology, University Hospital Marburg, Germany) for their excellent technical support. We also thank PD Dr. M. Bette (Institute of Anatomy and Cell Biology, Philipps-Universität Marburg) for the excellent support during microscopic evaluation. Finally, we also thank Dr. A. Schmidt and members of the Institute of Pathology and Molecular Pathology (University Hospital Marburg) for their collegial support and the provision of reagents. This study is part of the thesis work of M.O.

Funding

The study was funded by the foundation for tumor research head and neck (Stiftung für Tumorforschung Kopf-Hals), Wiesbaden, Germany.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local ethics committee (Landesärztekammer Rheinland-Pfalz) approved all of the experiments with human material in this article (Ethikvotum 837.387.11 (7929)). All applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. A corresponding animal test application (animal experiment G 12-1-037) for the experiments was approved by the Landesuntersuchungsamt Rheinland-Pfalz in Koblenz and thus meets all §8 Paragraph 3 (2) of the German Animal Welfare Act required preconditions.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Vigneswaran N, Williams MD (2014) Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 26:123–141CrossRefGoogle Scholar
  2. 2.
    Lippman SM, Spitz M, Trizna Z, Benner SE, Hong WK (1994) Epidemiology, biology, and chemoprevention of aerodigestive cancer. Cancer 74:2719–2725CrossRefGoogle Scholar
  3. 3.
    Bose P, Brockton NT, Dort JC (2013) Head and neck cancer: from anatomy to biology. Int J Cancer 133:2013–2023CrossRefGoogle Scholar
  4. 4.
    Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967CrossRefGoogle Scholar
  5. 5.
    Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM (2002) Statin therapy accelerates reendothelialization. Circulation 105:3017–3024CrossRefGoogle Scholar
  6. 6.
    Werner N, Nickenig G (2004) Vascular progenitor cells and atherogenesis. DMW Dtsch Med Wochenschr 129:1269–1275CrossRefGoogle Scholar
  7. 7.
    Ziebart T, Yoon C-H, Trepels T, Wietelmann A, Braun T, Kiessling F, Stein S, Grez M, Ihling C, Muhly-Reinholz M, Carmona G, Urbich C, Zeiher AM, Dimmeler S (2008) Sustained persistence of transplanted proangiogenic cells contributes to neovascularization and cardiac function after ischemia. Circ Res 103:1327–1334CrossRefGoogle Scholar
  8. 8.
    Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15:105–111CrossRefGoogle Scholar
  9. 9.
    Ratajska A, Jankowska-Steifer E, Czarnowska E, Olkowski R, Gula G, Niderla-Bielińska J, Flaht-Zabost A, Jasińska A (2016) Vasculogenesis and its cellular therapeutic applications. Cells Tissues OrgansGoogle Scholar
  10. 10.
    Sridharan V, Margalit DN, Lynch SA, Severgnini M, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD (2016) Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer 4:32CrossRefGoogle Scholar
  11. 11.
    Lin Y, Weisdorf DJ, Solovey A, Hebbel RP (2000) Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71–77CrossRefGoogle Scholar
  12. 12.
    Hur J, Yoon C-H, Kim H-S, Choi J-H, Kang H-J, Hwang K-K, Oh B-H, Lee M-M, Park Y-B (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24:288–293CrossRefGoogle Scholar
  13. 13.
    Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S (2005) Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39:733–742CrossRefGoogle Scholar
  14. 14.
    Khakoo AY, Finkel T (2005) Endothelial progenitor cells. Annu Rev Med 56:79–101CrossRefGoogle Scholar
  15. 15.
    Ziebart T, Blatt S, Günther C, Völxen N, Pabst A, Sagheb K, Kühl S, Lambrecht T (2016) Significance of endothelial progenitor cells (EPC) for tumorigenesis of head and neck squamous cell carcinoma (HNSCC): possible marker of tumor progression and neovascularization? Clin Oral Investig 20:2293–2300CrossRefGoogle Scholar
  16. 16.
    Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A, Roccaro AM, Ghobrial IM (2014) Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta 1846(1):26–39Google Scholar
  17. 17.
    Wildt S (2015) Hairless NOD scid mouse. 9018441Google Scholar
  18. 18.
    Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89:E1–E7CrossRefGoogle Scholar
  19. 19.
    Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S (2007) Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 28:766–772CrossRefGoogle Scholar
  20. 20.
    Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148–154CrossRefGoogle Scholar
  21. 21.
    Cardiff RD, Miller CH, Munn RJ (2014) Manual immunohistochemistry staining of mouse tissues using the avidin-biotin complex (ABC) technique. Cold Spring Harb Protoc 2014:659–662Google Scholar
  22. 22.
    Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682CrossRefGoogle Scholar
  23. 23.
    Ge YZ, Wu R, Lu TZ, Xin H, Yu P, Zhao Y, Liu H, Xu Z, Xu LW, Shen JW, Xu X, Zhou LH, Li WC, Zhu JG, Jia RP (2015) Circulating endothelial progenitor cell: a promising biomarker in clinical oncology. Med Oncol 32(1):332CrossRefGoogle Scholar
  24. 24.
    George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A, Mittelman A, Tiwari RK (2011) Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol 4:24CrossRefGoogle Scholar
  25. 25.
    Brunner M, Thurnher D, Heiduschka G, Grasl M, Brostjan C, Erovic BM (2008) Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients. J Surg Oncol 98(7):545–550CrossRefGoogle Scholar
  26. 26.
    Umemura T, Higashi Y (2008) Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci 108(1):1–6CrossRefGoogle Scholar
  27. 27.
    Hristov M, Erl W, Weber PC (2003) Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 23(7):1185–1189CrossRefGoogle Scholar
  28. 28.
    Moccia F, Poletto V (2015) May the remodeling of the Ca(2)(+) toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment? Biochim Biophys Acta 1853(9):1958–1973CrossRefGoogle Scholar
  29. 29.
    Laurenzana A, Margheri F, Chilla A, Biagioni A, Margheri G, Calorini L et al (2016) Endothelial progenitor cells as shuttle of anticancer agents. Hum Gene Ther 27:784–791CrossRefGoogle Scholar
  30. 30.
    Torimura T, Ueno T, Taniguchi E, Masuda H, Iwamoto H, Nakamura T, Inoue K, Hashimoto O, Abe M, Koga H, Barresi V, Nakashima E, Yano H, Sata M (2012) Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice. Cancer Sci 103(3):542–548CrossRefGoogle Scholar
  31. 31.
    Kaur S, Bajwa PA (2014) Tete-a tete’ between cancer stem cells and endothelial progenitor cells in tumor angiogenesis. Clin Transl Oncol 16(2):115–121CrossRefGoogle Scholar
  32. 32.
    Zhao X, Liu H-Q, Li J, Liu X-L (2016) Endothelial progenitor cells promote tumor growth and progression by enhancing new vessel formation. Oncol Lett 12:793–799CrossRefGoogle Scholar
  33. 33.
    Janic B, Arbab AS (2010) The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal 10:1088–1099CrossRefGoogle Scholar
  34. 34.
    Neuchrist C, Erovic BM, Handisurya A, Fischer MB, Steiner GE, Hollemann D, Gedlicka C, Saaristo A, Burian M (2003) Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25:464–474CrossRefGoogle Scholar
  35. 35.
    Ge Q, Zhang H, Hou J, Wan L, Cheng W, Wang X, Dong D, Chen C, Xia J, Guo J, Chen X, Wu X (2018) VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms. Mol Med Rep 17:1667–1675Google Scholar
  36. 36.
    Buttler K, Badar M, Seiffart V, Laggies S, Gross G, Wilting J, Weich HA (2014) De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice. Cell Mol Life Sci 71:1513–1527CrossRefGoogle Scholar
  37. 37.
    Parmar P, Marwah N, Parshad S, Yadav T, Batra A, Sen R (2018) Clinicopathological significance of tumor lymphatic vessel density in head and neck squamous cell carcinoma. Indian J Otolaryngol Head Neck Surg 70:102–110CrossRefGoogle Scholar
  38. 38.
    Mermod M, Bongiovanni M, Petrova TV, Dubikovskaya EA, Simon C, Tolstonog G, Monnier Y (2017) Correlation between podoplanin expression and extracapsular spread in squamous cell carcinoma of the oral cavity using subjective immunoreactivity scores and semiquantitative image analysis. Head Neck 39:98–108CrossRefGoogle Scholar
  39. 39.
    Li T, Wang G, Tan Y, Wang H (2014) Inhibition of lymphangiogenesis of endothelial progenitor cells with VEGFR-3 siRNA delivered with PEI-alginate nanoparticles. Int J Biol Sci 10:160–170CrossRefGoogle Scholar
  40. 40.
    Smith A, Teknos TN, Pan Q (2013) Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 49:287–292CrossRefGoogle Scholar
  41. 41.
    Aruga N, Kijima H, Masuda R, Onozawa H, Yoshizawa T, Tanaka M, Inokuchi S, Iwazaki M (2018) Epithelial-mesenchymal transition (EMT) is correlated with patient’s prognosis of lung squamous cell carcinoma. Tokai J Exp Clin Med 43:5–13Google Scholar
  42. 42.
    Joseph JP, Harishankar MK, Pillai AA, Devi A (2018) Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC. Oral Oncol 80:23–32CrossRefGoogle Scholar
  43. 43.
    Tania M, Khan MA, Fu J (2014) Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35:7335–7342CrossRefGoogle Scholar
  44. 44.
    Madonna R, De Caterina R (2015) Circulating endothelial progenitor cells: do they live up to their name? Vasc Pharmacol 67-69:2–5CrossRefGoogle Scholar
  45. 45.
    Fadini GP, Losordo D, Dimmeler S (2012) Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110:624–637CrossRefGoogle Scholar
  46. 46.
    Zhao Y, Yu P, Wu R, Ge Y, Wu J, Zhu J, Jia R (2013) Renal cell carcinoma-adjacent tissues enhance mobilization and recruitment of endothelial progenitor cells to promote the invasion of the neoplasm. Biomed Pharmacother 67:643–649CrossRefGoogle Scholar
  47. 47.
    Kong Z, Hong Y, Zhu J, Cheng X, Liu Y (2018) Endothelial progenitor cells improve functional recovery in focal cerebral ischemia of rat by promoting angiogenesis via VEGF. J Clin Neurosci 55:116–121CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Interdisciplinary Head & Neck Oncology Laboratory, Department for Oral and Maxillofacial SurgeryUniversity Hospital Giessen and MarburgMarburgGermany
  2. 2.Clinic for Oral and Maxillofacial SurgeryUniversity Medical Center MainzMainzGermany
  3. 3.Clinic for Oral and Maxillofacial SurgeryFederal Armed Forces Hospital KoblenzKoblenzGermany
  4. 4.Interdisciplinary Head & Neck Oncology Laboratory, Department of Otolaryngology, Head & Neck SurgeryUniversity Hospital MarburgMarburgGermany
  5. 5.Department of Mathematics and Computer Science, Research Group for BioinformaticsPhilipps-Universität MarburgMarburgGermany

Personalised recommendations